Identification of microRNA-451a as a Novel Circulating Biomarker for Colorectal Cancer Diagnosis

14Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background. Colorectal cancer (CRC) is one of the leading causes of cancer death worldwide. Successful treatment of CRC relies on accurate early diagnosis, which is currently a challenge due to its complexity and personalized pathologies. Thus, novel molecular biomarkers are needed for early CRC detection. Methods. Gene and microRNA microarray profiling of CRC tissues and miRNA-seq data were analyzed. Candidate microRNA biomarkers were predicted using both CRC-specific network and miRNA-BD tool. Validation analyses were carried out to interrogate the identified candidate CRC biomarkers. Results. We identified miR-451a as a potential early CRC biomarker circulating in patient's serum. The dysregulation of miR-451a was revealed both in primary tumors and in patients' sera. Downstream analysis validated the tumor suppressor role of miR-451a and high sensitivity of miR-451a in CRC patients, further confirming its potential role as CRC circulation biomarker. Conclusion. The miR-451a is a potential circulating biomarker for early CRC diagnosis.

Cite

CITATION STYLE

APA

Zhang, Z., Zhang, D., Cui, Y., Qiu, Y., Miao, C., & Lu, X. (2020). Identification of microRNA-451a as a Novel Circulating Biomarker for Colorectal Cancer Diagnosis. BioMed Research International, 2020. https://doi.org/10.1155/2020/5236236

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free